跳至主要内容
临床试验/ACTRN12622001337763
ACTRN12622001337763招募中未知

The Potential Benefits of Ginger Supplementation in Individuals With Iron Deficiency: a Randomised Controlled Pilot Study

The Oaks Medical Practice0 个研究点目标入组 20 人开始时间: 2022年10月18日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Adults aged 18 and over
  • 2. Confirmed iron deficiency (ID) diagnosis with SF level less than 30 µg/L with normal or slightly lower than normal Hb level (Hb greater than or equal to 110 g/L)
  • 3. Adequately maintained liver and renal functions with the following laboratory
  • parameters less than 2x Upper Limit of Normal:
  • a. Alanine transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT)
  • b. Blood urea nitrogen (BUN) and creatinine
  • 4. Functional grade based on ECOG Performance Status is between 0 to 2
  • 5. Received explanation of the purpose and methods of the study and provided written
  • consent at the point of recruitment

排除标准

  • 1. A mental health condition that may impede the patient’s ability to provide informed consent
  • 2. Having diagnosed with an eating disorder or demonstrating certain behavioural, physical and psychological signs or changes that often accompany an eating disorder
  • 3. Known or possible pregnancy, desire to become pregnant during the study period, or currently breastfeeding
  • 4. Known to have an allergy to ginger or had experienced adverse reactions to ginger previously
  • 5. Underwent any major surgery within 6 months at the time of screening or planning to undergo a major surgery during the study period
  • 6. Had any blood transfusion to replace blood lost due to surgery or injury within the last 6 months or need to receive a blood transfusion during the study period
  • 7. Having underlying pathology and sources of overt and occult blood loss (e.g., GIT, genitourinary, nose, mouth, etc.) that was diagnosed or currently under investigation
  • 8. Donating blood within 8 weeks of starting the trial or during the study period
  • 9. Having underlying conditions due to chronic disease (e.g. inflammatory bowel disease, celiac disease, autoimmune gastritis, rheumatoid arthritis, etc.), liver disease, B12 deficiency, or malignancy
  • 10. Having active infections or other medical conditions that elevate SF and high sensitivity C-reactive protein (hsCRP) acutely
  • 11. Previous treatment of ID with oral iron therapy within the last 1 month or intravenous iron therapy within the last 3 months
  • 12. Currently on warfarin or any other blood-thinning medications (anticoagulants)
  • 13. No concurrently taking other dietary supplement of iron, vitamin C, probiotics, vitamin B12, folic acid, and vitamin D during the trial

研究者

发起方
The Oaks Medical Practice

相似试验